[Tumor resistance to HER2 inhibitors: the drug sedimentation concept]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The human epidermal growth factor receptor 2 (HER2) oncogene plays a crucial role in mammary carcinogenesis.
• Trastuzumab and lapatinib are established anti-HER2 targeted therapies for breast cancer.
• Tumor resistance limits the long-term efficacy of current HER2-targeted treatments.

Purpose of the Study:

• To explore novel therapeutic agents and strategies to overcome resistance to HER2-targeted therapies.
• To propose a new treatment paradigm, the "sedimentation strategy," for managing metastatic breast cancer.
• To integrate recent concepts like oncogene addiction and tumor dormancy into treatment planning.

Main Methods:

• Review of existing literature on HER2 oncogene, carcinogenesis, and targeted therapies.
• Analysis of mechanisms underlying resistance to trastuzumab and lapatinib.
• Conceptual development of a multi-agent "sedimentation strategy."

Main Results:

• While HER2 amplification/overexpression is key, it's insufficient to guarantee treatment response due to resistance.
• Understanding resistance mechanisms opens avenues for novel therapeutic agents.
• The proposed "sedimentation strategy" aims to combine distinct targeted approaches.

Conclusions:

• Novel agents are needed to bypass resistance mechanisms in HER2-positive breast cancer.
• The "sedimentation strategy" offers a framework for combining therapies to address oncogene addiction, dormancy, and residual disease.
• This approach holds promise for improving outcomes in metastatic breast cancer patients.